Protocol Ledger

NCT04764448 · Phase II · TERMINATED

A Study of Belcesiran in Patients With AATLD

Interventional Phase II clinical trial protocol NCT04764448 sponsored by Novo Nordisk in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-02-12 Enrollment: 16 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04764448
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)16 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04764448
Protocol FieldVerified Registry Value
NCT IdentifierNCT04764448
Consolidated Lead SponsorNovo Nordisk
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment16 participants (ACTUAL)
Registered Start Date2021-02-12
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04764448
Hospital Research SiteLocationSite Profile
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->
University of FloridaGainesville, FLOpen Hospital Dossier ->
Medical University of South CarolinaCharleston, SCOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI